Diabetes mellitus and congestive heart failure: Specificities of ethiopathogenesis and treatment;Diabète sucré et décompensation cardiaque: Spécificités éthiopathogéniques et thérapeutiques

Revue Medicale Suisse

Volumn 2, Issue 76, 2006, Pages 1893-1900

  De Flines, Jenny ^a   Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SPIRONOLACTONE; SULFAMIDE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG TOLERANCE; HEART FAILURE; HUMAN; HYPERTENSION; METABOLIC DISORDER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS;

DIABETES MELLITUS, TYPE 2; HEART FAILURE, CONGESTIVE; HUMANS; RISK FACTORS;

EID: 33748946748     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
2. Bell DSH. Heart failure. The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433-41.
3. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
4. Scheen AJ. Combined thiazolidinedione-insulin therapy. Should we be concerned about safety? Drug Safety 2004;27:841-56.
5. Tenenbaum A, Motro M, Fisman EZ, et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 2003;114:271-5.
6. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999;20:789-95.
7. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham Study. Am J Cardiol 1974;34:29-34.
8. Nichols GA, Erbey JR, Hillier TA, et al. Congestive heart failure in type 2 diabetes: Prevalence, incidence, and risk factors. Diabetes Care 2001;23:1614-9.
9. Fonarow GC. An approach to heart failure and diabetes mellitus. Am J Cardiol 2005;96(Suppl.4A):47E-52.
10. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
11. McGavock JM, Victor RG, Unger RH et al. Adiposity of the heart, revisited. Ann Intern Med 2006;144:517-24.
12. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: Management of hypertensive heart disease. Prog Cardiovasc Dis 2006;48:326-41.
13. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension 2001;37:1053-9.
14. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543-67.
15. Vinik A, Maser R. Mitchell B, et al. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553-79.
16. Nesto RW. Pharmacological treatment and prevention of heart failure in the diabetic patient Rev Cardiovasc Med 2004;5:115-26.
17. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Available at http://www.acc.org (Accessed August 28, 2004).
18. Bukharovich IF, Kukin M. Optimal medical therapy for heart failure. Prog Cardiovasc Dis 2006;48:372-85.
19. Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004;47:116-30.
20. Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. The renin-angiotensin system and the long-term complications of diabetes: Pathophysiological and therapeutic considerations. Diabet Med 2003;20:607-21.
21. Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
22. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004;64:2537-65.
23. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists. Circulation 2004;109:2492-9.
24. van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: Controversial or common sense? Eur Heart J 2005;26:2361-7.
25. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
26. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
27. Thohan V, Torre-Amione G, Koerner MM. Aldosterone antagonism and congestive heart failure: A new look at an old therapy. Curr Opin Cardiol 2004;19:301-8.
28. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: Review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004;9:243-55.
29. Williams RE. Early initiation of beta blockade in heart failure: Issues and evidence. J Clin Hypertens 2005;7:520-8.
30. Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint Herz 2004;29:290-8.
31. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: Systematic review and meta-analysis. Arch Intern Med 2003;163:2594-602.
32. Special issue. Cardiovascular benefits of metformin. Diabetes Metab 2003;29(Suppl):6S5-6S122.
33. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
34. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51.
35. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
36. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
37. Dormandy J, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
38. Tang WHW, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394-8.
39. Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: Critical appraisal for the clinician. Circulation 2003;107:1350-4.
40. Riveline JP, Danchin N, Ledru F, Varroud-Vial N, Charpentier G. Sulfonylureas and cardiovascular effects: From experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003;29:207-22.
41. Chiasson J-L, Josse RG, Gomis R et al for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 2003;290:486-94.
42. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6.